EVALUATING AND REPORTING DYSPHAGIA IN TRIALS OF CHEMOIRRADIATION FOR HEAD-AND-NECK CANCER

被引:29
作者
Gluck, Iris [1 ]
Feng, Felix Y. [1 ]
Lyden, Teresa [2 ]
Haxer, Marc [2 ]
Worden, Francis [3 ]
Chepeha, Douglas B. [4 ]
Eisbruch, Avraham [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Speech Pathol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Otolaryngol Head Neck Surg, Ann Arbor, MI 48109 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2010年 / 77卷 / 03期
关键词
Dysphagia; Swallowing; Head-and-neck cancer; Chemoirradiation; Quality of life; CTCAE v3; QUALITY-OF-LIFE; PHASE-II TRIAL; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; THERAPY-ONCOLOGY-GROUP; INTENSITY-MODULATED RADIOTHERAPY; ACCELERATED RADIATION-THERAPY; PROSPECTIVE RANDOMIZED-TRIAL; CONCOMITANT BOOST RADIATION; ORGAN PRESERVATION;
D O I
10.1016/j.ijrobp.2009.05.049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Reporting long-term toxicities in trials of chemoirradiation (CRT) of head-and-neck cancer (HNC) has mostly been limited to observer-rated maximal Grades >= 3. We evaluated this reporting approach for dysphagia by assessing patient-reported dysphagia (PRD) and objective swallowing dysfunction through videofluoroscopy (VF) in patients with various grades of maximal observer-reported dysphagia (ORD). Methods and Materials: A total of 62 HNC patients completed quality-of-life questionnaires periodically through 12 months post-CRT. Five PRD items were selected: three dysphagia-specific questions, an Eating-Domain, and "Overall Bother." They underwent VF at 3 and 12 months, and ORD (Common Terminology Criteria for Adverse Events) scoring every 2 months. We classified patients into four groups (0-3) according to maximal ORD scores documented 3-12 months post-CRT, and assessed PRD and VF summary scores in each group. Results: Differences in ORD scores among the groups were considerable throughout the observation period. In contrast, PRD scores were similar between Groups 2 and 3, and variable in Group 1. VF scores were worse in Group 3 compared with 2 at 3 months but similar at 12 months. In Group 1, PRD and VF scores from 3 through 12 months were close to Groups 2 and 3 if ORD score 1 persisted, but were similar to Group 0 in patients whose ORD scores improved by 12 months. Conclusions: Patients with lower maximal ORD grades, especially if persistent, had similar rates of PRD and objective dysphagia as patients with highest grades. Lower ORD grades should therefore be reported. These findings may have implications for reporting additional toxicities besides dysphagia. (C) 2010 Elsevier Inc.
引用
收藏
页码:727 / 733
页数:7
相关论文
共 52 条
[41]   Adverse event reporting in publications compared with sponsor database for cancer clinical trials [J].
Scharf, Orit ;
Colevas, A. Dimitrios .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3933-3938
[42]   Statistical issues in studies of toxicity modifiers [J].
Scott, C .
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :91-96
[43]   Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer [J].
Staar, S ;
Rudat, V ;
Stuetzer, H ;
Dietz, A ;
Volling, P ;
Schroeder, M ;
Flentje, M ;
Eckel, HE ;
Mueller, RP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (05) :1161-1171
[44]   Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer [J].
Sunwoo, JB ;
Herscher, LL ;
Kroog, GS ;
Thomas, GR ;
Ondrey, FG ;
Duffey, DC ;
Solomon, BI ;
Boss, C ;
Albert, PS ;
McCullugh, L ;
Rudy, S ;
Muir, C ;
Zhai, S ;
Figg, WD ;
Cook, JA ;
Mitchell, JB ;
Van Waes, C .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :800-811
[45]  
Terrell JE, 1997, ARCH OTOLARYNGOL, V123, P1125
[46]   CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment [J].
Trotti, A ;
Colevas, AD ;
Setser, A ;
Rusch, V ;
Jaques, D ;
Budach, V ;
Langer, C ;
Murphy, B ;
Cumberlin, R ;
Coleman, CN ;
Rubin, P .
SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (03) :176-181
[47]   Patient-reported outcomes and the evolution of adverse event reporting in oncology [J].
Trotti, Andy ;
Colevas, A. Dimitrios ;
Setser, Ann ;
Basch, Ethan .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (32) :5121-5127
[48]   TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group [J].
Trotti, Andy ;
Pajak, Thomas F. ;
Gwede, Clement K. ;
Paulus, Rebecca ;
Cooper, Jay ;
Forastiere, Arlene ;
Ridge, John A. ;
Watkins-Bruner, Deborah ;
Garden, Adam S. ;
Ang, K. Kian ;
Curran, Wally .
LANCET ONCOLOGY, 2007, 8 (07) :613-624
[49]   Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck [J].
Tsao, Anne S. ;
Garden, Adam S. ;
Kies, Merrill S. ;
Morrison, William ;
Feng, Lei ;
Lee, J. Jack ;
Khuri, Fadlo ;
Zinner, Ralph ;
Myers, Jeffery ;
Papadimitrakopoulou, Vassiliki ;
Lewin, Jan ;
Clayman, Gary L. ;
Ang, K. Kian ;
Glisson, Bonnie S. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4163-4169
[50]   Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer [J].
Vokes, EE ;
Stenson, K ;
Rosen, FR ;
Kies, MS ;
Rademaker, AW ;
Witt, ME ;
Brockstein, BE ;
List, MA ;
Fung, BB ;
Portugal, L ;
Mittal, BB ;
Pelzer, H ;
Weickselbaum, RR ;
Haraf, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :320-326